Authors: Amati, L.; Caradonna, L.; Leandro, G.; Magrone, T.; Minenna, M.; Faleo, G.; Pellegrino, N. M.; Jirillo, E.; Caccavo, D.

Source: Current Drug Metabolism, Volume 9, Number 24, September 2003 , pp. 1937-1945(9)

Publisher: Bentham Science Publishers

Abstract:

Proinflammatory cytokines released from monocytes / macrophages, in particular tumor necrosis factor (TNF)-, interleukin (IL)-1, IL-6, and IL-8 seem to play an important role in Inflammatory Bowel Disease (ulcerative colitis and Crohn's disease).

Endotoxins or lipopolysaccharides, derived from the outer membrane of Gram-negative bacteria interact with CD14 on surface membrane of macrophages, thus triggering a signal cascade, which leads to the production and release of proinflammatory cytokines, particularly TNF-. Therefore, in IBD, lipopolysaccharides could play a pathogenic role. In this respect, plasma endotoxins have been demonstrated in a not negligible percentage of patients with ulcerative colitis and in their unaffected relatives.

The presence of circulating endotoxins could be due, at least in part, to the impaired natural immunity in either patients with ulcerative colitis or in their first degree unaffected relatives.

Lactoferrin is an iron-binding glycoprotein, which binds to the lipid A region of lipopolysaccharide with a high affinity and this interaction prevents the binding of lipopolysaccharide to CD14, thus inhibiting the release of proinflammatory cytokines. Therefore, based on the possible pathogenic role exerted by endotoxins in ulcerative colitis, lactoferrin may deserve attention as a possible therapeutical agent in experimental models of Inflammatory Bowel Disease.

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612033454324

Affiliations: 1: Immunologia, Policlinico, Piazza G. Cesare 4, 70124 Bari, Italy.

Publication date: 2003-09-01

More about this publication?

• Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
  
  Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Amati, L. ;  Caradonna, L. ;  Leandro, G. ;  Magrone, T. ;  Minenna, M. ;  Faleo, G. ;  Pellegrino, N. M. ;  Jirillo, E. ;  Caccavo, D.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers